Invokana Tablet, Film Coated
Product Images NDC 50090-5034

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Invokana (NDC 50090-5034). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Invokana 01)

Chemical structure diagram of canagliflozin, showing its molecular framework including aromatic rings, hydroxyl groups, and a sulfur-containing heterocycle, with an indication of half a water molecule (1/2 H2O) associated.*

FDA Label Image

Figure 1 (Invokana 02)

Line graph depicting the least squares mean change in HbA1c (%) from baseline with standard error over 52 weeks of study. Three treatments are compared: Canagliflozin 100 mg, Canagliflozin 300 mg, and Glimepiride, with data points shown from week 0 to week 52 and a last observation carried forward (LOCF) at week 52.*

FDA Label Image

Figure 2 (Invokana 03)

A line graph showing the least squares mean change in HbA1c (%) from baseline over a 52-week study period. Two treatment groups are compared: Canagliflozin 300 mg and Sitagliptin 100 mg, with data points including standard error bars. The x-axis represents study weeks, and the y-axis represents percentage change in HbA1c from baseline.*

FDA Label Image

Figure 3 (Invokana 04)

A line graph comparing the percentage of subjects with events over time in weeks for Cana (canagliflozin) versus placebo groups. The graph includes a hazard ratio (HR) with 95% confidence interval (CI) of 0.86 (0.75, 0.97). The x-axis represents time in weeks, and the y-axis shows the percentage of subjects with events. A table below the graph lists the number of subjects remaining at various time points for each group.*

FDA Label Image

Figure 4 (Invokana 05)

A line graph comparing the percentage of subjects with events over time in weeks for canagliflozin (Cana) versus placebo groups. The graph shows cumulative incidence over approximately 182 weeks, with a hazard ratio of 0.70 (95% CI: 0.59, 0.82) favoring canagliflozin. The number of subjects at risk at various time points is listed below the graph for both placebo and canagliflozin groups.*

FDA Label Image

Label Image (Lbl500905034)

Label for INVOKANA 100 mg film-coated tablets, containing canagliflozin, manufactured by A-S Medication Solutions. The label specifies the product NDC 50090-5034-0 and states storage instructions at 68 to 77 degrees Fahrenheit. The package contains 90 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.